• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Transfusion Transmission of Hepatitis A Virus during a Recent Epidemic in Europe

February 21, 2023

In most infections of hepatitis A (HAV), individuals have very mild symptoms or are asymptomatic.  Although rare in the U.S., globally HAV causes about 1.4 million cases and usually spreads via fecal-oral routes; however, case reports have documented transmission by sexual contact and transfusion.  An HAV outbreak occurred in Europe from 2016 to 2019, and researchers detected a rising number of HAV cases in Poland between mid-2017 and 2019.  To better understand the transfusion-transmission potential of HAV, researchers in Poland screened 1,866,590 blood donations from 1,210,423 donors in mini-pools for HAV between 2017 to 2019.  During the outbreak, 28 HAV positive blood donations from 21 donors were identified (n=13 donors from 2017, n=6 from 2018, and n=2 from 2019).  A total of 54 HAV positive blood components were prepared, and 37 units were transfused (23/27 HAV positive RBC units, 13/27 platelets, and 1/28 plasma units).  Of the 12 HAV positive blood components that were traced after transfusion to seven patients, two cases of transfusion-transmitted HAV were identified (28.6%)—one asymptomatic and one symptomatic infection.  Follow-up samples from 20-HAV infected donors revealed HAV-RNA persisted for a maximum of 125 days.  Based on these results and the identification of a HAV reactive donor after vaccination, a 6-month donor deferral after HAV infection and 14 days post HAV vaccination may be prudent to protect patients from HAV transfusion-transmission.

Reference:

Sulkowska E, Masny A, Kalińska A, Kopacz A, Kubicka-Russel D, Marek M, Parczewski M, Radłowski D, Jaroszewicz J, Trzcińska A, Łetowska M, Grabarczyk P; Group of Polish Blood Transfusion Centers for blood borne pathogens. Hepatitis A virus (HAV) RNA detection in Polish blood donors and likely transmissions through blood components during the 2017-2019 epidemic. Transfusion. 2023 Feb;63(2):349-359.

 

Filed Under

  • News
  • Transfusion Transmitted Infections

Recommended

  • Gut Microbe Exoglycosidases Target ABO Blood Group Antigens to Generate ABO-Universal Blood

  • New FDA Draft Guidance to Reduce Transfusion-Transmitted Malaria

  • A New, Simple Proxy to Measure Oxygen Unloading and the Quality of Stored Blood

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

  • Prothrombin Complex Concentrate Is Safe and Effective for Cardiac Surgery Patients with Coagulopathic Bleeding

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley